Do analysts recommend TACO or PARK?

Park Dental Partners has a consensus target price of $28.50, suggesting a potential upside of 50.00%. Given Park Dental Partners' stronger consensus rating and higher possible upside, analysts plainly believe Park Dental Partners is more favorable than Berto Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Park Dental Partners 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, TACO or PARK?

Berto Acquisition has higher earnings, but lower revenue than Park Dental Partners. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Berto Acquisition N/A N/A N/A N/A N/A Park Dental Partners $244.49M 0.37 -$360K $1.05 18.10

Is TACO or PARK more profitable?

Company Net Margins Return on Equity Return on Assets Berto Acquisition N/A N/A N/A Park Dental Partners N/A N/A N/A

Park Dental Partners (PARK) Competitors

$19.06 +0.06 (+0.33%)

As of 10:17 AM Eastern

Compare

PARK vs. VMD, TACO, BDSX, INFU, and XGN

Should you buy Park Dental Partners stock or one of its competitors? Park Dental Partners's main competitors and comparable companies include Viemed Healthcare (VMD), Berto Acquisition (TACO), Biodesix (BDSX), InfuSystem (INFU), and Exagen (XGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Park Dental Partners compare to Viemed Healthcare?

Park Dental Partners (NASDAQ:PARK) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

74.2% of Viemed Healthcare shares are held by institutional investors. 10.6% of Park Dental Partners shares are held by company insiders. Comparatively, 20.6% of Viemed Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Park Dental Partners presently has a consensus price target of $28.50, indicating a potential upside of 50.00%. Viemed Healthcare has a consensus price target of $14.00, indicating a potential upside of 44.48%. Given Park Dental Partners' stronger consensus rating and higher possible upside, analysts plainly believe Park Dental Partners is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Viemed Healthcare has a net margin of 4.81% compared to Park Dental Partners' net margin of 0.00%. Viemed Healthcare's return on equity of 10.16% beat Park Dental Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
Viemed Healthcare	4.81%	10.16%	7.22%

In the previous week, Park Dental Partners and Park Dental Partners both had 2 articles in the media. Viemed Healthcare's average media sentiment score of 0.61 beat Park Dental Partners' score of 0.41 indicating that Viemed Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Park Dental Partners	Neutral
Viemed Healthcare	Positive

Viemed Healthcare has higher revenue and earnings than Park Dental Partners. Park Dental Partners is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.37	-$360K	$1.05	18.10
Viemed Healthcare	$270.28M	1.37	$14.93M	$0.36	26.92

Summary

Viemed Healthcare beats Park Dental Partners on 9 of the 13 factors compared between the two stocks.

How does Park Dental Partners compare to Berto Acquisition?

Berto Acquisition (NASDAQ:TACO) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Berto Acquisition	N/A	N/A	N/A
Park Dental Partners	N/A	N/A	N/A

In the previous week, Berto Acquisition had 1 more articles in the media than Park Dental Partners. MarketBeat recorded 3 mentions for Berto Acquisition and 2 mentions for Park Dental Partners. Berto Acquisition's average media sentiment score of 1.56 beat Park Dental Partners' score of 0.41 indicating that Berto Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
Berto Acquisition	Very Positive
Park Dental Partners	Neutral

Berto Acquisition has higher earnings, but lower revenue than Park Dental Partners.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Berto Acquisition	N/A	N/A	N/A	N/A	N/A
Park Dental Partners	$244.49M	0.37	-$360K	$1.05	18.10

Park Dental Partners has a consensus target price of $28.50, suggesting a potential upside of 50.00%. Given Park Dental Partners' stronger consensus rating and higher possible upside, analysts plainly believe Park Dental Partners is more favorable than Berto Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Park Dental Partners beats Berto Acquisition on 5 of the 7 factors compared between the two stocks.

How does Park Dental Partners compare to Biodesix?

Park Dental Partners (NASDAQ:PARK) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Park Dental Partners presently has a consensus price target of $28.50, indicating a potential upside of 50.00%. Biodesix has a consensus price target of $36.25, indicating a potential upside of 51.10%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Biodesix	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Park Dental Partners has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.37	-$360K	$1.05	18.10
Biodesix	$88.50M	2.86	-$35.26M	-$3.17	N/A

In the previous week, Biodesix had 3 more articles in the media than Park Dental Partners. MarketBeat recorded 5 mentions for Biodesix and 2 mentions for Park Dental Partners. Biodesix's average media sentiment score of 1.31 beat Park Dental Partners' score of 0.41 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Park Dental Partners	Neutral
Biodesix	Positive

Park Dental Partners has a net margin of 0.00% compared to Biodesix's net margin of -26.97%. Park Dental Partners' return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
Biodesix	-26.97%	-788.19%	-30.33%

21.0% of Biodesix shares are owned by institutional investors. 10.6% of Park Dental Partners shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Biodesix beats Park Dental Partners on 8 of the 14 factors compared between the two stocks.

How does Park Dental Partners compare to InfuSystem?

Park Dental Partners (NASDAQ:PARK) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Park Dental Partners had 1 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for Park Dental Partners and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.67 beat Park Dental Partners' score of 0.41 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
Park Dental Partners	Neutral
InfuSystem	Positive

InfuSystem has a net margin of 1.12% compared to Park Dental Partners' net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Park Dental Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
InfuSystem	1.12%	2.78%	1.41%

InfuSystem has lower revenue, but higher earnings than Park Dental Partners. Park Dental Partners is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.37	-$360K	$1.05	18.10
InfuSystem	$143.34M	1.91	$870K	$0.41	33.17

Park Dental Partners currently has a consensus target price of $28.50, indicating a potential upside of 50.00%. InfuSystem has a consensus target price of $17.50, indicating a potential upside of 28.68%. Given Park Dental Partners' higher possible upside, equities analysts clearly believe Park Dental Partners is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
InfuSystem	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

71.1% of InfuSystem shares are owned by institutional investors. 10.6% of Park Dental Partners shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

InfuSystem beats Park Dental Partners on 10 of the 15 factors compared between the two stocks.

How does Park Dental Partners compare to Exagen?

Exagen (NASDAQ:XGN) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Park Dental Partners has a net margin of 0.00% compared to Exagen's net margin of -26.61%. Park Dental Partners' return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Park Dental Partners	N/A	N/A	N/A

75.3% of Exagen shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 10.6% of Park Dental Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Park Dental Partners has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.06	-$19.95M	-$0.81	N/A
Park Dental Partners	$244.49M	0.37	-$360K	$1.05	18.10

Exagen currently has a consensus price target of $9.75, indicating a potential upside of 15.80%. Park Dental Partners has a consensus price target of $28.50, indicating a potential upside of 50.00%. Given Park Dental Partners' higher possible upside, analysts clearly believe Park Dental Partners is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Exagen and Exagen both had 2 articles in the media. Exagen's average media sentiment score of 1.28 beat Park Dental Partners' score of 0.41 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
Park Dental Partners	Neutral

Summary

Park Dental Partners beats Exagen on 8 of the 13 factors compared between the two stocks.

Get Park Dental Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PARK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PARK vs. The Competition

Export

Metric	Park Dental Partners	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$91.27M	$10.41B	$7.43B	$12.75B
Dividend Yield	N/A	2.61%	2.52%	19.59%
P/E Ratio	18.26	34.04	274.89	25.07
Price / Sales	0.37	4.67	568.47	74.22
Price / Cash	4.46	115.88	76.68	52.75
Price / Book	3.58	5.15	10.37	5.90
Net Income	-$360K	$315.68M	$3.49B	$380.43M
7 Day Performance	-7.46%	0.05%	-3.10%	-4.14%
1 Month Performance	-7.95%	-4.23%	-7.39%	-6.70%
1 Year Performance	N/A	9.59%	1.29%	-6.43%

Park Dental Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PARK Park Dental Partners	2.9261 of 5 stars	$19.06 +0.3%	$28.50 +49.5%	N/A	$91.27M	$244.49M	18.26	1,212	Short Interest Increase
VMD Viemed Healthcare	3.7065 of 5 stars	$9.36 +1.2%	$14.00 +49.7%	+40.6%	$356.31M	$301.61M	25.99	1,382
TACO Berto Acquisition	1.4506 of 5 stars	$10.47 +0.0%	N/A	-0.8%	$341.21M	N/A	N/A	7,892	Positive News Short Interest Decrease
BDSX Biodesix	4.6345 of 5 stars	$28.30 -2.6%	$35.00 +23.7%	+208.0%	$297.18M	$102.94M	N/A	334	Positive News Analyst Forecast
INFU InfuSystem	3.3594 of 5 stars	$13.33 -1.2%	$17.50 +31.3%	+48.8%	$267.61M	$143.34M	221.04	473	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PARK) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Park Dental Partners (PARK) Competitors

PARK vs. VMD, TACO, BDSX, INFU, and XGN

How does Park Dental Partners compare to Viemed Healthcare?

Summary

How does Park Dental Partners compare to Berto Acquisition?

Summary

How does Park Dental Partners compare to Biodesix?

Summary

How does Park Dental Partners compare to InfuSystem?

Summary

How does Park Dental Partners compare to Exagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PARK vs. The Competition

Park Dental Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Park Dental Partners (PARK) Competitors

PARK vs. VMD, TACO, BDSX, INFU, and XGN

How does Park Dental Partners compare to Viemed Healthcare?

Do insiders and institutionals believe in PARK or VMD?

Do analysts prefer PARK or VMD?

Is PARK or VMD more profitable?

Does the media prefer PARK or VMD?

Which has better earnings and valuation, PARK or VMD?

Summary

How does Park Dental Partners compare to Berto Acquisition?

Is TACO or PARK more profitable?

Does the media refer more to TACO or PARK?

Which has stronger earnings & valuation, TACO or PARK?

Do analysts recommend TACO or PARK?

Summary

How does Park Dental Partners compare to Biodesix?

Do analysts recommend PARK or BDSX?

Which has higher earnings and valuation, PARK or BDSX?

Does the media refer more to PARK or BDSX?

Is PARK or BDSX more profitable?

Do institutionals and insiders believe in PARK or BDSX?

Summary

How does Park Dental Partners compare to InfuSystem?

Does the media refer more to PARK or INFU?

Is PARK or INFU more profitable?

Which has preferable valuation and earnings, PARK or INFU?

Do analysts recommend PARK or INFU?

Do institutionals & insiders believe in PARK or INFU?

Summary

How does Park Dental Partners compare to Exagen?

Is XGN or PARK more profitable?

Do insiders & institutionals believe in XGN or PARK?

Which has better valuation and earnings, XGN or PARK?

Do analysts rate XGN or PARK?

Does the media refer more to XGN or PARK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PARK vs. The Competition

Park Dental Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools